SELLAS Life Sciences Group Inc (SLS)
1.55
+0.05
(+3.33%)
USD |
NASDAQ |
Apr 19, 13:53
SELLAS Life Sciences Group Cash from Financing (TTM): 22.32M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 22.32M |
September 30, 2023 | 19.86M |
June 30, 2023 | 19.91M |
March 31, 2023 | 42.94M |
December 31, 2022 | 24.08M |
September 30, 2022 | 23.20M |
June 30, 2022 | 25.34M |
March 31, 2022 | 9.121M |
December 31, 2021 | 12.07M |
September 30, 2021 | 35.70M |
June 30, 2021 | 41.95M |
March 31, 2021 | 35.14M |
December 31, 2020 | 38.44M |
September 30, 2020 | 17.09M |
June 30, 2020 | 8.783M |
March 31, 2020 | 23.64M |
December 31, 2019 | 19.57M |
September 30, 2019 | 17.17M |
June 30, 2019 | 31.24M |
March 31, 2019 | 20.61M |
December 31, 2018 | 23.12M |
September 30, 2018 | 7.664M |
June 30, 2018 | 8.826M |
March 31, 2018 | 10.27M |
December 31, 2017 | 5.534M |
Date | Value |
---|---|
September 30, 2017 | 4.814M |
June 30, 2017 | 6.532M |
March 31, 2017 | -2.751M |
December 31, 2016 | 16.50M |
September 30, 2016 | 31.75M |
June 30, 2016 | 13.86M |
March 31, 2016 | 21.81M |
December 31, 2015 | 43.84M |
September 30, 2015 | 54.70M |
June 30, 2015 | 55.13M |
March 31, 2015 | 50.82M |
December 31, 2014 | 24.26M |
September 30, 2014 | 22.10M |
June 30, 2014 | 60.17M |
March 31, 2014 | 70.58M |
December 31, 2013 | 55.95M |
September 30, 2013 | 70.82M |
June 30, 2013 | 33.44M |
March 31, 2013 | 40.37M |
December 31, 2012 | 42.43M |
September 30, 2012 | 19.88M |
June 30, 2012 | 20.70M |
March 31, 2012 | 14.06M |
December 31, 2011 | 19.20M |
September 30, 2011 | 19.16M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
8.783M
Minimum
Jun 2020
42.94M
Maximum
Mar 2023
24.61M
Average
23.20M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
Geron Corp | 362.02M |
Immuneering Corp | 28.44M |
Protagonist Therapeutics Inc | 170.48M |
Akebia Therapeutics Inc | -25.21M |
Moderna Inc | -1.377B |